Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.

Sharma A, Broggini-Tenzer A, Vuong V, Messikommer A, Nytko KJ, Guckenberger M, Bachmann F, Lane HA, Pruschy M.

Radiother Oncol. 2017 Sep;124(3):433-438. doi: 10.1016/j.radonc.2017.07.024. Epub 2017 Aug 7.

PMID:
28797699
2.

Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.

Schneider H, Szabo E, Machado RA, Broggini-Tenzer A, Walter A, Lobell M, Heldmann D, Süssmeier F, Grünewald S, Weller M.

J Neurochem. 2017 Jan;140(1):170-182. doi: 10.1111/jnc.13877. Epub 2016 Dec 12.

3.

Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.

Sharma A, Bender S, Zimmermann M, Riesterer O, Broggini-Tenzer A, Pruschy MN.

Clin Cancer Res. 2016 Sep 1;22(17):4428-39. doi: 10.1158/1078-0432.CCR-15-2449. Epub 2016 Apr 13.

4.

Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.

Meerang M, Bérard K, Felley-Bosco E, Lauk O, Vrugt B, Boss A, Kenkel D, Broggini-Tenzer A, Stahel RA, Arni S, Weder W, Opitz I.

Mol Cancer Ther. 2016 May;15(5):1095-105. doi: 10.1158/1535-7163.MCT-15-0583. Epub 2016 Feb 2.

5.

Combined treatment strategies for microtubule stabilizing agent-resistant tumors.

Broggini-Tenzer A, Sharma A, Nytko KJ, Bender S, Vuong V, Orlowski K, Hug D, O'Reilly T, Pruschy M.

J Natl Cancer Inst. 2015 Feb 17;107(4). pii: dju504. doi: 10.1093/jnci/dju504. Print 2015 Apr.

PMID:
25694444
6.

Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma†.

Meerang M, Boss A, Kenkel D, Broggini-Tenzer A, Bérard K, Lauk O, Arni S, Weder W, Opitz I.

Eur J Cardiothorac Surg. 2015 Jan;47(1):e34-41. doi: 10.1093/ejcts/ezu393. Epub 2014 Oct 25.

7.

Ionizing radiation induces tumor cell lysyl oxidase secretion.

Shen CJ, Sharma A, Vuong DV, Erler JT, Pruschy M, Broggini-Tenzer A.

BMC Cancer. 2014 Jul 22;14:532. doi: 10.1186/1471-2407-14-532.

8.

The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion.

Furmanova-Hollenstein P, Broggini-Tenzer A, Eggel M, Millard AL, Pruschy M.

Radiat Oncol. 2013 Apr 30;8:105. doi: 10.1186/1748-717X-8-105.

9.

Dynamics of tumor hypoxia in response to patupilone and ionizing radiation.

Orlowski K, Rohrer Bley C, Zimmermann M, Vuong V, Hug D, Soltermann A, Broggini-Tenzer A, Pruschy M.

PLoS One. 2012;7(12):e51476. doi: 10.1371/journal.pone.0051476. Epub 2012 Dec 10.

10.

Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.

Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, Weniger D, Lütolf UM, Knuth A, Yonekawa Y, Barath K, Broggini-Tenzer A, Pruschy M, Hofer S.

Oncology. 2012;83(1):1-9. doi: 10.1159/000339152. Epub 2012 Jun 8.

11.

Microtubule stabilising agents and ionising radiation: multiple exploitable mechanisms for combined treatment.

Rohrer Bley C, Furmanova P, Orlowski K, Grosse N, Broggini-Tenzer A, McSheehy PM, Pruschy M.

Eur J Cancer. 2013 Jan;49(1):245-53. doi: 10.1016/j.ejca.2012.05.008. Epub 2012 Jun 7. Review.

12.

The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.

Oehler C, von Bueren AO, Furmanova P, Broggini-Tenzer A, Orlowski K, Rutkowski S, Frei K, Grotzer MA, Pruschy M.

Neuro Oncol. 2011 Sep;13(9):1000-10. doi: 10.1093/neuonc/nor069. Epub 2011 Jul 9.

13.

Metabolism of tumors under treatment: mapping of metabolites with quantitative bioluminescence.

Broggini-Tenzer A, Vuong V, Pruschy M.

Radiother Oncol. 2011 Jun;99(3):398-403. doi: 10.1016/j.radonc.2011.05.041. Epub 2011 Jun 12.

PMID:
21665309
14.

Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study.

Riesterer O, Oehler-Jänne C, Jochum W, Broggini-Tenzer A, Vuong V, Pruschy M.

Radiat Oncol. 2011 Jun 8;6:66. doi: 10.1186/1748-717X-6-66.

15.

A novel concept for scaffold-free vessel tissue engineering: self-assembly of microtissue building blocks.

Kelm JM, Lorber V, Snedeker JG, Schmidt D, Broggini-Tenzer A, Weisstanner M, Odermatt B, Mol A, Zünd G, Hoerstrup SP.

J Biotechnol. 2010 Jul 1;148(1):46-55. doi: 10.1016/j.jbiotec.2010.03.002. Epub 2010 Mar 17.

PMID:
20223267
16.

Substrate screening identifies a novel target sequence for the proteasomal activity regulated by ionizing radiation.

Broggini-Tenzer A, Hollenstein A, Pianowski Z, Wampfler A, Furmanova P, Winssinger N, Pruschy M.

Proteomics. 2010 Jan;10(2):304-14. doi: 10.1002/pmic.200900162.

PMID:
19957288
17.

Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models.

Oehler-Jänne C, Jochum W, Riesterer O, Broggini-Tenzer A, Caravatti G, Vuong V, Pruschy M.

Mol Cancer Ther. 2007 Sep;6(9):2496-504.

18.

Current concepts for the combined treatment modality of ionizing radiation with anticancer agents.

Oehler C, Dickinson DJ, Broggini-Tenzer A, Hofstetter B, Hollenstein A, Riesterer O, Vuong V, Pruschy M.

Curr Pharm Des. 2007;13(5):519-35. Review.

PMID:
17348847
19.

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M.

Clin Cancer Res. 2005 Feb 15;11(4):1588-96.

Supplemental Content

Loading ...
Support Center